WO2002081020A3 - Method for preventing acute renal failure - Google Patents

Method for preventing acute renal failure Download PDF

Info

Publication number
WO2002081020A3
WO2002081020A3 PCT/US2002/010539 US0210539W WO02081020A3 WO 2002081020 A3 WO2002081020 A3 WO 2002081020A3 US 0210539 W US0210539 W US 0210539W WO 02081020 A3 WO02081020 A3 WO 02081020A3
Authority
WO
WIPO (PCT)
Prior art keywords
ketoalkanoic acid
renal failure
acute renal
preventing acute
subject
Prior art date
Application number
PCT/US2002/010539
Other languages
French (fr)
Other versions
WO2002081020A2 (en
Inventor
Mitchell P Fink
H Shaw Warren
Original Assignee
Critical Therapeutics Inc
Mitchell P Fink
H Shaw Warren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Therapeutics Inc, Mitchell P Fink, H Shaw Warren filed Critical Critical Therapeutics Inc
Priority to AU2002254525A priority Critical patent/AU2002254525B2/en
Priority to JP2002579058A priority patent/JP2004527529A/en
Priority to CA002441542A priority patent/CA2441542A1/en
Priority to EP02723759A priority patent/EP1377339A4/en
Publication of WO2002081020A2 publication Critical patent/WO2002081020A2/en
Publication of WO2002081020A3 publication Critical patent/WO2002081020A3/en
Priority to US10/679,040 priority patent/US20040068006A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

Disclosed is a method of treating acute renal failure in a subject. The method comprises the step of administering to the subject an effective amount of a composition comprising a 2-ketoalkanoic acid, a pharmaceutically acceptable salt of a 2-ketoalkanoic acid, an ester of a 2-ketoalkanoic acid, or an amide of a 2-ketoalkanoic acid. Preferably, the composition comprises an enolization agent and an alkyl aralkyl, alkoxyalkyl or carboxyalkyl ester of a 2-ketoalkanoic acid dissolved in a pharmaceutically acceptable vehicle.
PCT/US2002/010539 2001-04-04 2002-04-03 Method for preventing acute renal failure WO2002081020A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002254525A AU2002254525B2 (en) 2001-04-04 2002-04-03 Method for preventing acute renal failure
JP2002579058A JP2004527529A (en) 2001-04-04 2002-04-03 Methods to prevent acute renal failure
CA002441542A CA2441542A1 (en) 2001-04-04 2002-04-03 Method for preventing acute renal failure
EP02723759A EP1377339A4 (en) 2001-04-04 2002-04-03 Method for preventing acute renal failure
US10/679,040 US20040068006A1 (en) 2001-04-04 2003-10-03 Method for preventing acute renal failure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28136301P 2001-04-04 2001-04-04
US60/281,363 2001-04-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/679,040 Continuation-In-Part US20040068006A1 (en) 2001-04-04 2003-10-03 Method for preventing acute renal failure

Publications (2)

Publication Number Publication Date
WO2002081020A2 WO2002081020A2 (en) 2002-10-17
WO2002081020A3 true WO2002081020A3 (en) 2003-01-09

Family

ID=23076972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010539 WO2002081020A2 (en) 2001-04-04 2002-04-03 Method for preventing acute renal failure

Country Status (6)

Country Link
US (1) US20040068006A1 (en)
EP (1) EP1377339A4 (en)
JP (1) JP2004527529A (en)
AU (1) AU2002254525B2 (en)
CA (1) CA2441542A1 (en)
WO (1) WO2002081020A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877141B1 (en) 2005-04-15 2013-06-12 Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
US9173422B2 (en) * 2009-12-29 2015-11-03 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4752619A (en) * 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia
US4908214A (en) * 1987-07-23 1990-03-13 Synthelabo Pharmaceutical tablet for the treatment of uraemia
US4957938A (en) * 1989-06-21 1990-09-18 Abbott Laboratories Nutritional formulation for the treatment of renal disease
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4380549A (en) * 1975-07-23 1983-04-19 Scott Eugene J Van Topical treatment of dry skin
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4812479A (en) * 1981-04-01 1989-03-14 The Montefiore Hospital Society Of Western Pennsylvania, Inc. Method for preventing body fat deposition in mammals
US4645764A (en) * 1981-04-01 1987-02-24 Montefiore Hospital Method for preventing body fat deposition in animals
US4548937A (en) * 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
US5100677A (en) * 1985-12-18 1992-03-31 Veech Richard L Fluid therapy with various organic anions
US4820823A (en) * 1985-02-27 1989-04-11 Director-General Of Agency Of Industrial Science And Technology Process of producing α-keto acids
DE3581407D1 (en) * 1985-09-06 1991-02-21 Nestle Sa STORAGE OF LIVING TISSUE.
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US6051609A (en) * 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5147650A (en) * 1988-07-29 1992-09-15 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5238684A (en) * 1988-07-29 1993-08-24 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4874790A (en) * 1988-08-15 1989-10-17 Montefiore Hospital Association Of Western Pennsylvania Method for improving the glucose metabolism of an animal having diabetic tendencies
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
US5075210A (en) * 1989-12-21 1991-12-24 The Regents Of The University Of California Preservation of the heart for transplantation
US5134162A (en) * 1990-12-24 1992-07-28 The Montefiore Hospital Association Of Western Pennsylvania Method for lowering high blood cholesterol levels in hyperlipidemic animals and confections as the ingestion medium
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
WO1993006726A1 (en) * 1991-09-30 1993-04-15 Mackenzie Walser Methods for treatment of free-radical-mediated tissue injury
US5674865A (en) * 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa
US5294641A (en) * 1991-11-27 1994-03-15 Montefiore - University Hospital Method for treating a medical patient for cardiac trauma
US5508308A (en) * 1992-04-16 1996-04-16 Abbott Laboratories Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
CA2164321C (en) * 1993-06-04 2002-08-20 Paul E. Segall Plasma-like solution
US5395822A (en) * 1993-09-20 1995-03-07 Izumi; Yukitoshi Use of pyruvate to prevent neuronal degeneration associated with ischemia
US5612374A (en) * 1994-02-14 1997-03-18 Ronald T. Stanko Inhibiting growth of mammary adenocarcinoma
US5523459A (en) * 1994-03-25 1996-06-04 Ube Industries, Ltd. Preparation of α-keto acid ester
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5801198A (en) * 1995-07-13 1998-09-01 University Of Pittsburgh Medical Center Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US5667962A (en) * 1996-03-18 1997-09-16 Case Western Reserve University Pyruvate thiolester for the prevention of reperfusion injury
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
GB9724813D0 (en) * 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
JP2004528307A (en) * 2001-03-15 2004-09-16 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Use of pyruvate and / or derivatives thereof for the treatment of inflammatory conditions mediated by cytokines
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4752619A (en) * 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia
US4908214A (en) * 1987-07-23 1990-03-13 Synthelabo Pharmaceutical tablet for the treatment of uraemia
US4957938A (en) * 1989-06-21 1990-09-18 Abbott Laboratories Nutritional formulation for the treatment of renal disease
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure

Also Published As

Publication number Publication date
CA2441542A1 (en) 2002-10-17
AU2002254525B2 (en) 2004-12-23
WO2002081020A2 (en) 2002-10-17
EP1377339A4 (en) 2006-05-31
EP1377339A2 (en) 2004-01-07
JP2004527529A (en) 2004-09-09
US20040068006A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
WO2003007802A3 (en) Pharmaceutical combinations of oxycodone and naloxone
BR0013704A (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular cases
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
CA2437844A1 (en) Method for increasing leptin levels using nicotinic acid compounds
WO2005032555A3 (en) Pharmaceutical combinations of hydrocodone and naltrexone
WO2003002243A3 (en) Method and device for electrochemical formation of therapeutic species in vivo
WO2003072040A3 (en) Administration of agents for the treatment of inflammation
WO2002013766A3 (en) Valproic acid derivatives for the treatment of pain
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
TW200420549A (en) Thiazole derivatives
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
MY130441A (en) Solutions containing epinastin
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2003088956A8 (en) Method for treating ileus with an alpha -ketoalkanoic acid or - ester or - amide
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
WO2006028991A3 (en) Composition and method for prevention or treatment of stomatits
CA2368165A1 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
WO2002081020A3 (en) Method for preventing acute renal failure
EP1090635A3 (en) Use of ferulic acid for treating hypertension
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
EP1847527A4 (en) Novel benzamidine compound
WO2001015693A3 (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002254525

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2441542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002723759

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10679040

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002579058

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002723759

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002254525

Country of ref document: AU